About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Rheumatoid Arthritis Clinical Trials in Houston | 2,948 Studies | Clareo Health

Clinical Trials Rheumatoid ArthritisHouston

Rheumatoid Arthritis Clinical Trials in Houston

Find 2,948 clinical trials for rheumatoid arthritis near Houston, Texas. Connect with research centers in your area.

All Rheumatoid Arthritis trials nationwide All trials in Houston

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 1321-1340 of 2,948 trials

COMPLETEDNA< 1 mile

Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine Cancer

NCT02592356

The goal of this clinical research study is to learn about possible weight, muscle, and/or fat loss in patients receiving cabozantinib or lenvatinib.

Differentiated Thyroid Gland CarcinomaMalignant Adrenal Gland PheochromocytomaMalignant Paraganglioma+1 more

M.D. Anderson Cancer Center23 participantsStarted Nov 2015

Houston, Texas, United States

COMPLETED< 1 mile

A Clinical Utility Study of PrismRA for Rheumatoid Arthritis

NCT05161234

A clinical utility study for PrismRA testing therapeutic response in patients with rheumatoid arthritis.

Rheumatoid Arthritis

Scipher Medicine613 participantsStarted Mar 2022

Chandler, Arizona, United States • Covina, California, United States • Hemet, California, United States +27 more locations

Rheumatoid Arthritis Trials in Other Cities

New York Los Angeles Chicago Phoenix Philadelphia San Antonio

Data from ClinicalTrials.govTerms

TERMINATEDNA< 1 mile

OCS Lung System EXPAND II Trial

NCT03343535

To evaluate the safety and effectiveness of the OCS™ Lung System to recruit, preserve and assess non-ideal donor lungs that may not meet current standard donor lung acceptance criteria for transplantation.

Lung Transplantation

TransMedics46 participantsStarted Mar 2018

Phoenix, Arizona, United States • Los Angeles, California, United States • San Francisco, California, United States +11 more locations

COMPLETEDPhase 2< 1 mile

Afimoxifene in Reducing the Risk of Breast Cancer in Women With Mammographically Dense Breast

NCT03063619

This randomized phase II trial studies how well afimoxifene works in reducing the risk of breast cancer in women with mammographically dense breast. Estrogen can cause the growth of breast cancer cells. Hormone therapy using afimoxifene may fight breast cancer by blocking the use of estrogen by the tumor cells.

Mammographically Dense Breast

M.D. Anderson Cancer Center194 participantsStarted Jan 2018

Tampa, Florida, United States • Chicago, Illinois, United States • Boston, Massachusetts, United States +2 more locations

TERMINATED< 1 mile

A Prospective, Global, Multi-center, Treatment Registry Study of Intravenous Immunoglobulin Maintenance Therapy in Alloantibody Positive Renal Allograft Recipients

NCT02115503

The purpose of this treatment registry study is to determine if monthly infusions of Intravenous Immunoglobulin (IVIg) for 6 months will neutralize donor specific antibodies that are thought to be responsible for chronic rejection episodes in renal transplant subjects. 162 renal transplant subjects will receive IVIg 5% at 2gm/kg/month for 6 months and be followed for 3 years.

Renal Transplant Recipients With Anti-HLA Antibodies

Databean52 participantsStarted Jul 2014

Los Angeles, California, United States • Sacramento, California, United States • Aurora, Colorado, United States +5 more locations

COMPLETEDPhase 3< 1 mile

Open-label Long-Term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD

NCT04143217

Open label, flexible dose, long-term multicenter study of safety and efficacy of SPN-812 in adult ADHD patients

Attention-Deficit/Hyperactivity Disorder

Supernus Pharmaceuticals, Inc.159 participantsStarted Jan 2020

Beverly Hills, California, United States • Garden Grove, California, United States • Los Alamitos, California, United States +35 more locations

COMPLETEDPhase 3< 1 mile

Treatment of Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor

NCT00085202

Drugs used in chemotherapy, such as vincristine, cisplatin, and cyclophosphamide, work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining radiation therapy with chemotherapy may kill more tumor cells. Autologous stem cell transplant may be able to replace blood-forming cells that were destroyed by chemotherapy or radiation therapy. It is not yet known which radiation therapy regimen combined with chemotherapy and donor stem cell transplant is more effective in treating medulloblastoma, supratentorial primitive neuroectodermal tumor, or atypical teratoid rhabdoid tumor. This phase III trial is studying two different regimens of radiation therapy when given together with chemotherapy and autologous stem cell transplant to see how well they work in treating patients with newly diagnosed medulloblastoma, supratentorial primitive neuroectodermal tumor, or atypical teratoid rhabdoid tumor. PRIMARY OBJECTIVE: * To assess the relationship between ERBB2 protein expression in tumors and progression-free survival probability for patients with medulloblastoma. * To estimate the frequency of mutations associated with SHH and WNT tumors (as defined by gene expression profiling) via targeted sequencing performed in an independent cohort of WNT and SHH tumors (also defined by gene expression profiling).

Brain and Central Nervous System Tumors

St. Jude Children's Research Hospital416 participantsStarted Aug 2003

Durham, North Carolina, United States • Philadelphia, Pennsylvania, United States • Memphis, Tennessee, United States +6 more locations

TERMINATEDPhase 3< 1 mile

Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent

NCT04844749

To demonstrate the efficacy of VERU-111 (Sabizabulin) in the treatment of metastatic castration-resistant prostate cancer in patients who have failed prior treatment with at least one androgen receptor targeting agent as measured by radiographic progression-free survival.

Metastatic Castration-resistant Prostate CancerAndrogen Resistant Prostatic Cancer

Veru Inc.105 participantsStarted Jun 2021

Anchorage, Alaska, United States • Tucson, Arizona, United States • Tucson, Arizona, United States +37 more locations

COMPLETED< 1 mile

Evaluation of Real-World Data on the Performance of the TECNIS Odyssey™ IOL

NCT05991960

Retrospective collection of data from medical records, multicenter, post-market clinical follow-up study.

Johnson & Johnson Surgical Vision, Inc.96 participantsStarted Sep 2023

Beverly Hills, California, United States • Largo, Florida, United States • Sarasota, Florida, United States +9 more locations

COMPLETEDNA< 1 mile

ILLUMENATE Pivotal Post-Approval Study (PAS)

NCT03421561

The ILLUMENATE Pivotal PAS is a continued follow-up study which will include 300 subjects from forty-three (43) sites across the United States and Austria previously enrolled in the ILLUMENATE Pivotal pre-market study to evaluate the Stellarex DCB compared to the PTA control device for the treatment of de-novo or post-PTA occluded/stenotic or reoccluded/restenotic (except for in-stent) SFA and/or popliteal arteries.

Peripheral Artery Disease

Spectranetics Corporation300 participantsStarted Jun 2013

Yuma, Arizona, United States • Fremont, California, United States • Los Angeles, California, United States +38 more locations

COMPLETEDPhase 2< 1 mile

VRC 705: A Zika Virus DNA Vaccine in Healthy Adults and Adolescents

NCT03110770

This was a multicenter, randomized study to evaluate the safety, immunogenicity, and efficacy of VRC-ZKADNA090-00-VP (Zika virus wildtype DNA vaccine) or placebo. In Part A, the primary objective was to evaluate the safety and tolerability of the vaccine in different vaccination regimens. In Part B, the primary objectives were to evaluate the safety and efficacy of the vaccine compared to placebo.

Zika VirusZika Virus InfectionVirus Diseases+4 more

National Institute of Allergy and Infectious Diseases (NIAID)2,428 participantsStarted Mar 2017

Miami, Florida, United States • Edinburg, Texas, United States • Houston, Texas, United States +14 more locations

COMPLETEDPhase 1< 1 mile

CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory CLL

NCT03739554

A Phase I Combination Study of CYC065 and Venetoclax for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Relapsed or Refractory Chronic Lymphocytic Leukemia

Cyclacel Pharmaceuticals, Inc.5 participantsStarted Jan 2019

Baltimore, Maryland, United States • Charlotte, North Carolina, United States • Houston, Texas, United States

COMPLETEDPhase 1/2< 1 mile

Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia

NCT01904136

This phase I/II studies the side effects and best dose of natural killer cells before and after donor stem cell transplant and to see how well they work in treating patients with acute myeloid leukemia, myelodysplastic syndrome, or chronic myelogenous leukemia. Giving chemotherapy with or without total body irradiation before a donor peripheral blood stem cell or bone marrow transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells and natural killer cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets.

Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveAcute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeAcute Myeloid Leukemia With Gene Mutations+6 more

M.D. Anderson Cancer Center54 participantsStarted Apr 2014

Houston, Texas, United States

COMPLETEDPhase 128 miles

A Study to Assess the Pharmacokinetics of Certolizumab Pegol in Adults With Active Rheumatoid Arthritis

NCT04740814

The purpose of the study is to evaluate the pharmacokinetics and safety of certolizumab pegol in adults with active rheumatoid arthritis.

Rheumatoid Arthritis

UCB Biopharma SRL33 participantsStarted Feb 2021

Phoenix, Arizona, United States • Covina, California, United States • Upland, California, United States +11 more locations

COMPLETEDPhase 128 miles

Study Evaluating the Treatment of OTX-TKI for Subjects With Neovascular Age-related Macular Degeneration

NCT04989699

Evaluate the safety, tolerability, and efficacy of OTX-TKI for intravitreal use in subjects with Neovascular Age-Related Macular Degeneration

Neovascular Age-Related Macular Degeneration

Ocular Therapeutix, Inc.21 participantsStarted Jul 2021

Bakersfield, California, United States • Oxnard, California, United States • Altamonte Springs, Florida, United States +3 more locations

TERMINATEDPhase 2/347 miles

Does a Rescue Course of Betamethasone in Pregnant Women With PPROM Decrease Neonatal Morbidity?

NCT02939742

The purpose of this study is to determine if a repeat course of betamethasone given to pregnant women with preterm premature rupture of membranes (PPROM) will decrease the infant's length of stay in the neonatal intensive care unit (NICU) and the overall neonatal morbidity associated with this condition.

PPROMRespiratory Distress Syndrome in Premature Infants

The University of Texas Medical Branch, Galveston33 participantsStarted Nov 2016

Galveston, Texas, United States

UNKNOWNPhase 2147 miles

Evaluation of Dupilumab in Patients With Atopic Keratoconjunctivitis (AKC)

NCT04296864

This is a multi-center, double-masked, randomized, placebo-controlled, parallel-group, efficacy, safety, and tolerability study evaluating the efficacy of Dupilumab in the treatment of signs and symptoms of atopic keratoconjunctivitis (AKC).

Atopic Keratoconjunctivitis

Andover Eye Associates42 participantsStarted Feb 2020

Los Angeles, California, United States • Littleton, Colorado, United States • Hollywood, Florida, United States +17 more locations

COMPLETEDPhase 3225 miles

A Comparative Study Between PF-06410293 and Humira® in Combination With Methotrexate in Participants With Active Rheumatoid Arthritis

NCT04230213

The study will assess the impact of pharmacokinetics (PK), safety and immunogenicity after switches between PF-06410293 and adalimumab and with continuous dosing with adalimumab in combination with methotrexate in subjects with moderately to severely active rheumatoid arthritis.

Rheumatoid Arthritis

Pfizer455 participantsStarted Jan 2020

Bowling Green, Kentucky, United States • Duncansville, Pennsylvania, United States • Dallas, Texas, United States +69 more locations

COMPLETEDPhase 1254 miles

A Pharmacokinetics Study of MK-7655A in Pediatric Participants With Gram-negative Infections (MK-7655A-020)

NCT03230916

This study aims to obtain plasma pharmacokinetic (PK) data and characterize the PK profile of imipenem (IMI), cilastatin (CIL), and relebactam (REL) following administration of a single intravenous (IV) dose of MK-7655A (a fixed ratio combination of imipenem/cilastatin/relebactam), hereafter referred to as IMI/REL.

Suspected or Documented Gram-negative Bacterial Infection

Merck Sharp & Dohme LLC47 participantsStarted Nov 2017

Little Rock, Arkansas, United States • Orange, California, United States • San Diego, California, United States +30 more locations

COMPLETED795 miles

Ascertaining the Radiologic Prognostic Importance of Extranodal Extension on Imaging (iENE) in Head and Neck Cancer

NCT05936502

Extranodal extension (ENE) refers to the spread of head and neck squamous cell carcinoma (HNSCC) outside the lymph nodes. It is a well-known factor that indicates a poorer prognosis and outcome for patients who have undergone surgical removal of the cancer. In such cases, it is recommended to combine chemotherapy with radiation therapy after surgery. As the number of cases of HNSCC related to the human papillomavirus (HPV) is increasing, treatment approaches have shifted towards using radiation therapy as the primary treatment method instead of surgery. This raises an important question about the significance of ENE observed through imaging tests (referred to as iENE) and its impact on the prognosis. Unfortunately, this question remains unanswered. The objective of this project is to conduct a comprehensive study across multiple medical institutions. The investigators will gather data including scan results, histopathology reports, and data from patient charts from individuals who have been treated for head and neck cancer. The aim is to analyze and correlate the findings between the pathological evidence of ENE and the imaging results, while also assessing the prognostic value of iENE. Additionally, the investigators will explore the influence of HPV status on these factors. By collecting and analyzing this data, the investigators hope to establish standardized criteria that can assist radiologists in accurately identifying ENE through imaging tests. This research is essential for enhancing our understanding of HNSCC and improving the effectiveness of diagnostic procedures and treatment planning.

Head and Neck Squamous Cell CarcinomaExtranodal ExtensionHuman Papilloma Virus Related Carcinoma

Head and Neck Cancer International Group3,500 participantsStarted Jul 2022

Omaha, Nebraska, United States • New York, New York, United States • Pittsburgh, Pennsylvania, United States +9 more locations

PreviousPage 67 of 148Next

Other Conditions in Houston

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia